This page summarizes information about the clinical trials that support investigation of both approved and experimental medicines. This information includes information about the interventions and their sponsoring organizations. Note that these data are derived from ClinicalTrials.gov, with information corrected and disambiguated to convey more accurate detail about these trials. Phase 4 trials are currently excluded on this page by default, as this data will be analyzed separately at a later date.
Trials with Experimental APIs
Top 5 (by most trials)
exendin (9-39) (47) ghrelin (38) glucagon-like peptide-1 (38) angiotensin 1-7 (34) cilengitide (30)Trials with Approved APIs
Top 5 (by most trials)
oxytocin (495) liraglutide (296) semaglutide (254) exenatide (204) octreotide (169)Trials with Unapproved APIs
Top 5 (by most trials)
NoneAPIs in Phase 1
Top 5 (by most trials)
oxytocin (113) semaglutide (87) liraglutide (73) exenatide (44) octreotide (33)APIs in Phase 2
Top 5 (by most trials)
liraglutide (171) oxytocin (167) semaglutide (153) exenatide (131) octreotide (110)APIs in Phase 3
Top 5 (by most trials)
liraglutide (110) semaglutide (99) exenatide (89) triptorelin (68) oxytocin (52)Phase 1 Sponsors
Top 5 (by most trials)
Novo Nordisk (132) Eli Lilly (72) Mayo Clinic (40) National Cancer Institute (NCI) (33) Harvard University (28)Phase 2 Sponsors
Top 5 (by most trials)
Eli Lilly (55) National Cancer Institute (NCI) (48) Novartis (45) Harvard University (41) Novo Nordisk (40)Phase 3 Sponsors
Top 5 (by most trials)
Novo Nordisk (139) Eli Lilly (107) AstraZeneca (54) Sanofi (40) Ipsen (38)